Short answer
Pediatrix Medical Group, Inc. (MD) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Second-quarter release covers operations for three and six months ended June 30, 2026.
Pediatrix Medical Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Second-quarter release covers operations for three and six months ended June 30, 2026
- Results details are contained in Exhibit 99.1, providing the primary basis for assessing quarterly performance
- Earnings disclosure may affect valuation, expectations, and near-term trading sentiment
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $487.8M, up 4.0% YoY, driven by acquisitions and reimbursement gains despite 2.1% lower same-unit volume
- Adjusted EPS $0.63 vs $0.53, while diluted shares fell to 81.4M from 85.5M after repurchases
- Adjusted EBITDA $76.4M vs $73.2M, but restructuring expenses rose to $8.5M from $3.8M
- Cash from operations $126.3M supported $42.7M share repurchases and $1.4M capital expenditures
- 2026 Adjusted EBITDA outlook reaffirmed at $280M-$300M; debt $584M with no revolver borrowings outstanding
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pediatrix Medical Group, Inc. 8-K filings
Get the next MD 8-K as it lands
Follow MD for push alerts, or ask the research agent what this filing means.